Press release
High-grade Glioma Market 2032: Epidemiology Trends, Innovative Therapies, Regulatory Approvals by DelveInsight | Everfront Biotech Co., Ltd., BioMimetix JV, LLC, Chimerix, Laminar Pharma
DelveInsight's "High-grade Glioma Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the High-grade Glioma, historical and forecasted epidemiology as well as the High-grade Glioma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the High-grade Glioma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; High-grade Glioma Market Forecast [https://www.delveinsight.com/sample-request/high-grade-glioma-hgg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the High-grade Glioma Market Report:
*
The High-grade Glioma market size was valued approximately USD 1.4 billion in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
*
In November 2023, BioMimetix revealed that its BMX-001, when administered alongside radiotherapy and temozolomide, extended the median survival of glioma patients by 6.6 months. Moreover, this treatment combination mitigated radiation-induced cognitive impairments and enhanced the integrity of white matter. These outcomes stem from the Phase II study (NCT02655601) conducted by the clinical-stage biotech, focusing on evaluating the candidate in patients with high-grade glioma (HGG).
*
The collective number of new cases of high-grade glioma (HGG) in the seven main markets was approximately 35,000 in 2022, with expectations of a rise over the study duration.
*
Some of the most hopeful upcoming medications in the high-grade glioma (HGG) developmental pipeline include Eflornithine, Regorafenib, Ofranergene, Obadenovec, AV-GBM-1, Tasadenoturev, VAL-083, ONC201, Selinexor, VBI-1901, Paxalisib, MDNA55, ITI-1000, and the combination of INO-5401, INO-9012, and Cemiplimab.
*
Throughout the research period from 2019 to 2032, the United States holds the largest market share for high-grade glioma (HGG), surpassing the combined market sizes of the EU4 countries, the UK, and Japan. In 2022 alone, the market size in the United States was estimated to exceed USD 900 million.
*
Key High-grade Glioma Companies: Everfront Biotech Co., Ltd., BioMimetix JV, LLC, Chimerix, Laminar Pharmaceuticals, Nationwide Children's Hospital, Rigel Pharmaceuticals, Orbus Therapeutics, BioMimetix, Bayer, MedImmune, DNAtrix, Chimerix, CNS Pharmaceuticals, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, DelMar Pharmaceuticals, Bristol-Myers Squibb, Laminar Pharmaceuticals, Immunomic Therapeutics, Inovio Pharmaceuticals, and others
*
Key High-grade Glioma Therapies: Cerebraca wafer, BMX-001, ONC201, LAM561, Ribociclib, Olutasidenib + TMZ, Eflornithine + Lomustine, BMX-001, Regorafenib, Durvalumab (MEDI4736), Tasadenoturev (DNX-2401), ONC201, Berubicin, VBI-1901, Paxalisib (GDC-0084), AV-GBM-1, MDNA55, VAL-083 (Dianhydrogalactitol), Pomalidomide, LP561A1 (2-OHOA), ITI-1000 (pp65 DC Vaccine), INO-5401+ INO-9012+ Cemiplimab (REGN2810), and others
*
The High-grade Glioma epidemiology based on gender analyzed that High-grade Glioma is more common in men than in women
*
The High-grade Glioma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage High-grade Glioma pipeline products will significantly revolutionize the High-grade Glioma market dynamics.
High-grade Glioma Overview
High-grade glioma (HGG) refers to a group of aggressive brain tumors that arise from glial cells, which are supportive cells in the brain and spinal cord. These tumors are characterized by their rapid growth and tendency to invade surrounding brain tissue. High-grade gliomas are classified as grade III or grade IV tumors based on their histological features and aggressiveness.
Get a Free sample for the High-grade Glioma Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/high-grade-glioma-hgg-market [https://www.delveinsight.com/report-store/high-grade-glioma-hgg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
High-grade Glioma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
High-grade Glioma Epidemiology Segmentation:
The High-grade Glioma market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
*
Total Prevalence of High-grade Glioma
*
Prevalent Cases of High-grade Glioma by severity
*
Gender-specific Prevalence of High-grade Glioma
*
Diagnosed Cases of Episodic and Chronic High-grade Glioma
Download the report to understand which factors are driving High-grade Glioma epidemiology trends @ High-grade Glioma Epidemiology Forecast [https://www.delveinsight.com/sample-request/high-grade-glioma-hgg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
High-grade Glioma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the High-grade Glioma market or expected to get launched during the study period. The analysis covers High-grade Glioma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the High-grade Glioma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
High-grade Glioma Therapies and Key Companies
*
Cerebraca wafer: Everfront Biotech Co., Ltd.
*
BMX-001: BioMimetix JV, LLC
*
ONC201: Chimerix
*
LAM561: Laminar Pharmaceuticals
*
Ribociclib: Nationwide Children's Hospital
*
Olutasidenib + TMZ: Rigel Pharmaceuticals
*
Eflornithine + Lomustine: Orbus Therapeutics
*
BMX-001: BioMimetix
*
Regorafenib: Bayer
*
Durvalumab (MEDI4736): MedImmune
*
Tasadenoturev (DNX-2401): DNAtrix
*
ONC201: Chimerix
*
Berubicin: CNS Pharmaceuticals
*
VBI-1901: VBI Vaccines
*
Paxalisib (GDC-0084): Kazia Therapeutics
*
AV-GBM-1: Aivita Biomedical
*
MDNA55: Medicenna Therapeutics
*
VAL-083 (Dianhydrogalactitol): DelMar Pharmaceuticals
*
Pomalidomide: Bristol-Myers Squibb
*
LP561A1 (2-OHOA): Laminar Pharmaceuticals
*
ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics
*
INO-5401+ INO-9012+ Cemiplimab (REGN2810): Inovio Pharmaceuticals
Discover more about therapies set to grab major High-grade Glioma market share @ High-grade Glioma Treatment Landscape [https://www.delveinsight.com/sample-request/high-grade-glioma-hgg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
High-grade Glioma Market Strengths
*
Rise in HGG market is attributed to several factors such as aging population, evolving research, more diagnostic tests, developing surgical approaches, improved radio therapy techniques and novel systemic therapies.
*
Improvement in genomics and proteomics can lead to an acceleration in the discovery of novel treatment and drug deliverance.
High-grade Glioma Market Opportunities
*
Increasing incidence trend will provide better therapeutic approaches for the HGG market in the near future.
*
The market of High-grade Glioma is currently using Temozolomide and Evacizumab as approved therapies, but the market lacks an effective strategy to cure HGG, which provides a lucrative opportunity to develop more treatment options.
Scope of the High-grade Glioma Market Report
*
Study Period: 2019-2032
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key High-grade Glioma Companies: Everfront Biotech Co., Ltd., BioMimetix JV, LLC, Chimerix, Laminar Pharmaceuticals, Nationwide Children's Hospital, Rigel Pharmaceuticals, Orbus Therapeutics, BioMimetix, Bayer, MedImmune, DNAtrix, Chimerix, CNS Pharmaceuticals, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, DelMar Pharmaceuticals, Bristol-Myers Squibb, Laminar Pharmaceuticals, Immunomic Therapeutics, Inovio Pharmaceuticals, and others
*
Key High-grade Glioma Therapies: Cerebraca wafer, BMX-001, ONC201, LAM561, Ribociclib, Olutasidenib + TMZ, Eflornithine + Lomustine, BMX-001, Regorafenib, Durvalumab (MEDI4736), Tasadenoturev (DNX-2401), ONC201, Berubicin, VBI-1901, Paxalisib (GDC-0084), AV-GBM-1, MDNA55, VAL-083 (Dianhydrogalactitol), Pomalidomide, LP561A1 (2-OHOA), ITI-1000 (pp65 DC Vaccine), INO-5401+ INO-9012+ Cemiplimab (REGN2810), and others
*
High-grade Glioma Therapeutic Assessment: High-grade Glioma current marketed and High-grade Glioma emerging therapies
*
High-grade Glioma Market Dynamics: High-grade Glioma market drivers and High-grade Glioma market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
High-grade Glioma Unmet Needs, KOL's views, Analyst's views, High-grade Glioma Market Access and Reimbursement
To know more about High-grade Glioma companies working in the treatment market, visit @ High-grade Glioma Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/high-grade-glioma-hgg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. High-grade Glioma Market Report Introduction
2. Executive Summary for High-grade Glioma
3. SWOT analysis of High-grade Glioma
4. High-grade Glioma Patient Share (%) Overview at a Glance
5. High-grade Glioma Market Overview at a Glance
6. High-grade Glioma Disease Background and Overview
7. High-grade Glioma Epidemiology and Patient Population
8. Country-Specific Patient Population of High-grade Glioma
9. High-grade Glioma Current Treatment and Medical Practices
10. High-grade Glioma Unmet Needs
11. High-grade Glioma Emerging Therapies
12. High-grade Glioma Market Outlook
13. Country-Wise High-grade Glioma Market Analysis (2019-2032)
14. High-grade Glioma Market Access and Reimbursement of Therapies
15. High-grade Glioma Market Drivers
16. High-grade Glioma Market Barriers
17. High-grade Glioma Appendix
18. High-grade Glioma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=highgrade-glioma-market-2032-epidemiology-trends-innovative-therapies-regulatory-approvals-by-delveinsight-everfront-biotech-co-ltd-biomimetix-jv-llc-chimerix-laminar-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release High-grade Glioma Market 2032: Epidemiology Trends, Innovative Therapies, Regulatory Approvals by DelveInsight | Everfront Biotech Co., Ltd., BioMimetix JV, LLC, Chimerix, Laminar Pharma here
News-ID: 3496263 • Views: …
More Releases from ABNewswire
Glass Mat MarketSize, Growth, Opportunities, Top Manufacturers, Share, Trends, S …
Glass Mat Market by Mat Type (Chopped Strand Mat, Continous Filament Mat), Binder Type (Emulsion, Powder), Manufacturing Process (Dry-Laid, Wet-Laid), End-Use Industry, Region (North America, APAC, Europe, Latin America, MEA) - Global Forecast to 2028
The glass mat market [https://www.marketsandmarkets.com/Market-Reports/glass-mat-market-32320559.html] size is estimated to be USD 1.3 billion in 2022 and is projected to grow at a CAGR of 8.6% between 2023 to 2028. The use of glass mat in the…
Chazin & Company Announces Three Grants to Arizona Nonprofits as Part of its Ina …
Mission driven financial solutions experts shows solidarity with Arizona community organizations.
Chazin & Company [https://www.chazinandcompany.com/], a leading provider of outsourced accounting and finance services for nonprofit organizations nationwide, today announced it has awarded three $5,000 unrestricted grants to Arizona nonprofits as part of its first-ever Roadshow event.
The May 20 Chazin Roadshow in Arizona is the first event in a series that Chazin & Company plans to hold around the country. Organizers…
YADAH Leads the Vegan Beauty Revolution with High-Quality, Eco-Friendly Products
Image: https://www.abnewswire.com/uploads/a226cf602a97874c8bfe654d3527841e.png
28th May, 2024 - Amidst the growing popularity of vegan cosmetics in the beauty market, YADAH (YADAH, CEO Kang Eun-mi) is at the forefront of the vegan beauty trend by developing products with high-quality ingredients that are not harmful to the skin.
Since its establishment in 2011, YADAH has consistently avoided the use of animal-derived or tested ingredients, harmful substances, even before "vegan beauty" became a trend. The company has…
Global Aircraft Electric Motors Market Set to Reach New Heights by 2027
The Global Aircraft Electric Motors Market Size is projected to grow from USD 8.2 billion in 2022 to USD 12.9 billion by 2027, at a CAGR of 9.4% from 2022 to 2027.
The global Aircraft Electric Motors [https://www.marketsandmarkets.com/Market-Reports/aircraft-electric-motors-market-3248447.html] Market is poised for significant growth, driven by advancements in electric propulsion technology and increasing demand for more efficient and environmentally friendly aircraft. According to a comprehensive report by MarketsandMarkets, titled "The Global…
More Releases for Glioma
Growth Dynamics of Adult Malignant Glioma Therapeutics Market
Increasing Prevalence of malignant glioma is a key factor driving the adult malignant glioma therapeutics market, says Fortune Business Insights in a report, titled "Adult Malignant Glioma Therapeutics Market Size, Share and Industry Analysis Product By Therapy (Chemotherapy, Radiotherapy, Targeted therapy) By Disease (Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma) By End User, and Regional Forecast 2019-2026." The global adult malignant glioma therapeutics market size was valued at USD 1,459.1 Million…
Malignant Glioma Market Trends & Projection to 2022
Malignant glioma’s are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. Gliomas account for around 45% of primary brain tumors where children are less likely to develop the risk of gliomas. Gliomas arise from the glial cells or non-neuronal cells hence the name and the cells are supposed to provide support and protection for neurons…
Optic Nerve Glioma Market Global Analysis & Forecast to 2023
Optic nerve glioma or optic glioma or juvenile pilocytic astrocytoma are types of brain tumour primarily affecting the optic nerve cells. Optic nerve gliomas are slow growing, rare and mostly found in children. Its occurrence in individuals over age 20 is quite rare and any occurrence is associated with the genetic disorder neurofibromatosis type 1, or NF1 in approximately 30% of the cases. Symptoms of an optic nerve glioma are…
Malignant Glioma Market to Significant Growth Foreseen by 2022
Malignant glioma’s are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. Gliomas account for around 45% of primary brain tumors where children are less likely to develop the risk of gliomas. Gliomas arise from the glial cells or non-neuronal cells hence the name and the cells are supposed to provide support and protection for neurons…
Malignant Glioma Pipeline Insight and Therapeutic Assessment 2017
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Malignant Glioma-Pipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Malignant Glioma. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Malignant Glioma by development stage, therapy type, route of…
Rising Number of People Diagnosed with Malignant Glioma Supports the Growth of t …
Glioma is a type of tumor that occurs in brain or spine. It is a group of brain tumor that includes oligodendrogliomas and astrocytomas. Gliomas include all types of brain tumors arising from supportive tissue of the brain. Malignant glioma is the most common type of brain tumor observed in adults globally. Collectively they contribute around 40% of the total cases diagnosed with brain tumor. In the last decade, there…
